Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (J⦠read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$14.07
Price+2.03%
$0.28
$708.583m
Small
58.6x
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$77.205m
-
1y CAGR-
3y CAGR-
5y CAGR$13.031m
-
1y CAGR-
3y CAGR-
5y CAGR$0.24
-
1y CAGR-
3y CAGR-
5y CAGR$224.848m
$426.035m
Assets$201.187m
Liabilities$46.457m
Debt10.9%
1x
Debt to EBITDA$244.776m
-
1y CAGR-
3y CAGR-
5y CAGR